Neoantigens in cancer immunotherapy.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38

Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 2.69

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016) 2.36

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

Gene therapy returns to centre stage. Nature (2015) 1.95

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol (2015) 1.48

The Basis of Oncoimmunology. Cell (2016) 1.47

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. J Immunother Cancer (2017) 1.39

Rekindling cancer vaccines. Nat Biotechnol (2016) 1.39

γδ T cells in cancer. Nat Rev Immunol (2015) 1.39

Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31

Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26

Targeting metastasis. Nat Rev Cancer (2016) 1.26

Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24

Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov (2015) 1.23

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist (2016) 1.18

Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13

Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12

Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity (2016) 1.11

Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer (2016) 1.08

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics (2015) 1.05

Elements of cancer immunity and the cancer-immune set point. Nature (2017) 1.05

Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 1.04

Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03

Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature (2016) 0.98

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci (2015) 0.97

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 0.96

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget (2016) 0.94

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clin Cancer Res (2015) 0.92

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92

Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Front Immunol (2015) 0.92

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92

Dendritic cell-derived exosomes for cancer therapy. J Clin Invest (2016) 0.91

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91

The role of neoantigens in response to immune checkpoint blockade. Int Immunol (2016) 0.90

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol (2015) 0.90

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget (2016) 0.90

Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89

PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res (2015) 0.89

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov (2015) 0.88

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget (2016) 0.88

Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer (2015) 0.88

Immune checkpoint inhibitors: a new frontier in bladder cancer. World J Urol (2015) 0.87

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv (2015) 0.86

Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Front Oncol (2015) 0.86

Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85

Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget (2015) 0.85

Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol (2016) 0.85

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. Semin Immunopathol (2017) 0.85

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci (2016) 0.85

The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biol Med (2015) 0.84

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol (2016) 0.84

Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci (2015) 0.84

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov (2016) 0.84

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res (2016) 0.83

Current progress in immunotherapy for pancreatic cancer. Cancer Lett (2015) 0.83

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. Proteomics (2016) 0.83

Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83

Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget (2016) 0.83

Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology (2015) 0.82

Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82

Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol (2015) 0.82

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol (2016) 0.82

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol (2015) 0.82

Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med (2016) 0.82

The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82

Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82

Dendritic cell-based immunotherapy. Cell Res (2016) 0.81

Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology (2016) 0.81

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep (2016) 0.81

Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discov (2015) 0.81

Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81

Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett (2016) 0.81

Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol (2016) 0.81

The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci (2016) 0.80

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80

Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80

Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clin Cancer Res (2015) 0.80

Epitope Recognition in the Human-Pig Comparison Model on Fixed and Embedded Material. J Histochem Cytochem (2015) 0.80

Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes. Cancer Immunol Immunother (2016) 0.80

Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80

Principles of immunology and its nuances in the central nervous system. Neuro Oncol (2015) 0.80

Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 0.80

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80

Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev (2016) 0.80

Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight (2016) 0.80

MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Hum Mutat (2016) 0.80

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79